Grupo Español De Linfomas Y Transplante Autólogo De Médula Ósea
Clinical trials sponsored by Grupo Español De Linfomas Y Transplante Autólogo De Médula Ósea, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise for rare lymphoma in Real-World study Results expected Nov 2026 (estimated)
- Engineered immune cells take on late-stage lymphoma in new trial Results expected Jan 2027 (estimated)
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThis observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New Pill-and-Infusion combo aims to tame rare blood cancer without chemo
Disease control Recruiting nowThis study tests a combination of two drugs, pirtobrutinib (a pill) and rituximab (an infusion), in 50 adults newly diagnosed with a slow-growing form of mantle cell lymphoma. The goal is to see if this drug pair can shrink or control the cancer without the need for standard chem…
Phase 2 • Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on late-stage lymphoma in new trial
Disease control Recruiting nowThis Phase 2 trial is testing a single infusion of axicabtagene ciloleucel, a CAR T-cell therapy, in 45 adults whose diffuse large B-cell lymphoma has returned more than a year after previous treatment. The main goal is to see how many patients have no signs of cancer on a PET/CT…
Phase 2 • Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC